Original article
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments

https://doi.org/10.1016/j.jaad.2020.12.058Get rights and content

Objective

To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic.

Study Design

The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation staff. Clinical questions relevant to the psoriatic disease community were informed by inquiries received by the National Psoriasis Foundation. A Delphi process was conducted.

Results

The TF updated evidence for the original 22 statements and added 5 new recommendations. The average of the votes was within the category of agreement for all statements, 13 with high consensus and 14 with moderate consensus.

Limitations

The evidence behind many guidance statements is variable in quality and/or quantity.

Conclusions

These statements provide guidance for the treatment of patients with psoriatic disease on topics including how the disease and its treatments affect COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge.

Key words

biologics
COVID-19
psoriasis
psoriatic arthritis
SARS-CoV-2
vaccines

Abbreviations used

CI
confidence interval
EUA
Emergency Use Authorization
FDA
US Food and Drug Administration
IL
interleukin
mRNA
messenger RNA
NPF
National Psoriasis Foundation
OR
odds ratio
PsA
psoriatic arthritis
RR
relative risk
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
TF
Task Force
TNFi
tumor necrosis factor inhibitors

Cited by (0)

Funding sources: None.

IRB approval status: Not applicable.

Reprints not available from the authors.

View Abstract